CICC Raises AKESO Price Target by 8.3% to HK$130, Keeps "Outperform Industry" Rating

Stock News09-17 14:12

CICC has released a research report noting that AKESO (09926) announced positive overall survival results from the registrational Phase III clinical trial (HARMONI-2) of its drug AK112, brand name Evdazen, compared with pembrolizumab as first-line treatment for PD-L1 positive non-small cell lung cancer (NSCLC), presented at WCLC.

Given the strong second-half data, the firm has raised the probability of success for the overseas H7 clinical trial, maintained its 2026 and 2027 earnings forecasts unchanged, and kept an "Outperform Industry" rating, lifting the target price by 8.3% to HK$130.

The firm points out this marks the first time a PD-1/VEGF bispecific antibody monotherapy has reported complete overall survival data in first-line NSCLC, with AK112 potentially redefining the treatment paradigm in this field. Currently, the international multicenter Phase III clinical study (HARMONi-7) of AK112 versus pembrolizumab as first-line therapy for PD-L1 positive NSCLC is continuing enrollment, and the firm believes the likelihood of success for this trial in the future is relatively high.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118931120?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-17 14:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118931120","market":"hk","top_or_hot":-1,"title":"CICC Raises AKESO Price Target by 8.3% to HK$130, Keeps \"Outperform Industry\" Rating","media":"Stock News","content":"<p>CICC has released a research report noting that <b>AKESO</b> (09926) announced positive overall survival results from the registrational Phase III clinical trial (HARMONI-2) of its drug AK112, brand name Evdazen, compared with pembrolizumab as first-line treatment for PD-L1 positive non-small cell lung cancer (NSCLC), presented at WCLC.<br><br>Given the strong second-half data, the firm has raised the probability of success for the overseas H7 clinical trial, maintained its 2026 and 2027 earnings forecasts unchanged, and kept an \"Outperform Industry\" rating, lifting the target price by 8.3% to HK$130.<br><br>The firm points out this marks the first time a PD-1/VEGF bispecific antibody monotherapy has reported complete overall survival data in first-line NSCLC, with AK112 potentially redefining the treatment paradigm in this field. Currently, the international multicenter Phase III clinical study (HARMONi-7) of AK112 versus pembrolizumab as first-line therapy for PD-L1 positive NSCLC is continuing enrollment, and the firm believes the likelihood of success for this trial in the future is relatively high.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CICC Raises AKESO Price Target by 8.3% to HK$130, Keeps \"Outperform Industry\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCICC Raises AKESO Price Target by 8.3% to HK$130, Keeps \"Outperform Industry\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-17 14:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CICC has released a research report noting that <b>AKESO</b> (09926) announced positive overall survival results from the registrational Phase III clinical trial (HARMONI-2) of its drug AK112, brand name Evdazen, compared with pembrolizumab as first-line treatment for PD-L1 positive non-small cell lung cancer (NSCLC), presented at WCLC.<br><br>Given the strong second-half data, the firm has raised the probability of success for the overseas H7 clinical trial, maintained its 2026 and 2027 earnings forecasts unchanged, and kept an \"Outperform Industry\" rating, lifting the target price by 8.3% to HK$130.<br><br>The firm points out this marks the first time a PD-1/VEGF bispecific antibody monotherapy has reported complete overall survival data in first-line NSCLC, with AK112 potentially redefining the treatment paradigm in this field. Currently, the international multicenter Phase III clinical study (HARMONi-7) of AK112 versus pembrolizumab as first-line therapy for PD-L1 positive NSCLC is continuing enrollment, and the firm believes the likelihood of success for this trial in the future is relatively high.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348735423.USD","symbol_name":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","start_time":0,"source_url":"","article_id":"1118931120","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118931120","pubTimestamp":1789625532,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CICC has released a research report noting that AKESO (09926) announced positive overall survival results from the registrational Phase III clinical trial (HARMONI-2) of its drug AK112, brand name...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","09926":"康方生物","LU1720050803.USD":"安联全方位中国股票基金","HELS":"Hedgeye 130/30 Equity ETF","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","EWH":"香港ETF-iShares MSCI","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","BK1161":"生物科技","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","BK1574":"生物医药B类股","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD"},"translate_title":"中金公司将AKESO目标价上调8.3%至130港元，维持“跑赢行业”评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWH":1,"HELS":1,"KURE":1,"09926":1},"content_text":"CICC has released a research report noting that AKESO (09926) announced positive overall survival results from the registrational Phase III clinical trial (HARMONI-2) of its drug AK112, brand name Evdazen, compared with pembrolizumab as first-line treatment for PD-L1 positive non-small cell lung cancer (NSCLC), presented at WCLC.Given the strong second-half data, the firm has raised the probability of success for the overseas H7 clinical trial, maintained its 2026 and 2027 earnings forecasts unchanged, and kept an \"Outperform Industry\" rating, lifting the target price by 8.3% to HK$130.The firm points out this marks the first time a PD-1/VEGF bispecific antibody monotherapy has reported complete overall survival data in first-line NSCLC, with AK112 potentially redefining the treatment paradigm in this field. Currently, the international multicenter Phase III clinical study (HARMONi-7) of AK112 versus pembrolizumab as first-line therapy for PD-L1 positive NSCLC is continuing enrollment, and the firm believes the likelihood of success for this trial in the future is relatively high.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118931120","isCrawlerRequest":true}